1-(3-fluoro-phenyl)-piperidine-4-carboxylic acid | 330985-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(3-fluoro-phenyl)-piperidine-4-carboxylic acid
• 英文别名: 1-(3-Fluorophenyl)piperidine-4-carboxylic acid
• CAS: 330985-22-3
• 化学式: C₁₂H₁₄FNO₂
• 分子量: 223.247
• InChiKey: GPZQWIBYKLVWNC-UHFFFAOYSA-N

物化性质

• 沸点：
  393.4±37.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3-fluoro-phenyl)-piperidine-4-carboxylic acid 、 6-氨基-2H-1,4-苯并吗啉-3(4H)-酮 生成 1-(3-Fluoro-phenyl)-piperidine-4-carboxylic acid (3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-amide
  参考文献：
  名称：

  Discovery of piperidine carboxamide TRPV1 antagonists

  摘要：

  A series of piperidine carboxamides were developed as potent antagonists of the transient receptor potential vanilloid-1 (TRPV1), an emerging target for the treatment of pain. A focused library of polar head groups led to the identification of a benzoxazinone amide that afforded good potency in cell-based assays. Synthesis and a QSAR model will be presented. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.035

文献信息

• 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor
  申请人：Calvo R. Raul

  公开号：US20060116368A1

  公开（公告）日：2006-06-01

  This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to hetero isonipecotic amides that are potent modulators of VR1 which are useful for the treatment and prevention of disease conditions in mammals.

  这项发明涉及辣椒素受体VR1配体。更具体地说，这项发明涉及对VR1具有潜在调节作用的杂环异尼泊酸酰胺，这些化合物对于治疗和预防哺乳动物的疾病状况是有用的。
• Substituted Dihydroquinazolines II
  申请人：Wunberg Tobias

  公开号：US20070281953A1

  公开（公告）日：2007-12-06

  The invention relates to substituted dihydroquinazolines and to a method for the production thereof, the use thereof for treating and/or preventing diseases and for producing drugs for treating and/or preventing diseases, in particular for the use of the inventive dihydroquinazolines in the form of antiviral agents, in particular against cytomegaloviruses.

  该发明涉及替代二氢喹唑啉化合物及其生产方法，以及用于治疗和/或预防疾病以及生产用于治疗和/或预防疾病的药物的用途，特别是创新二氢喹唑啉化合物作为抗病毒剂的用途，特别是针对巨细胞病毒。
• [EN] DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS DIHYDROPYRIMIDINE ET UTILISATIONS DE CEUX-CI EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2019001396A1

  公开（公告）日：2019-01-03

  Provided herein are a dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, provided herein is a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.

  本文提供了一种二氢嘧啶化合物及其药物应用，特别是用于治疗和预防HBV疾病的应用。具体来说，本文提供了具有化学式（I）或（Ia）的化合物，或其对映体、异构体、互变异构体、水合物、溶剂合物或其药用可接受的盐，其中化学式的变量如规范中定义。本文还提供了将具有化学式（I）或（Ia）的化合物，或其对映体、异构体、互变异构体、水合物、溶剂合物或其药用可接受的盐用作药物的用途，特别是用于治疗和预防HBV疾病。
• SUBSTITUIERTE DIHYDROCHINAZOLINE II
  申请人：Bayer HealthCare AG

  公开号：EP1685123B1

  公开（公告）日：2009-08-19
• DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE
  申请人：North & South Brother Pharmacy Investment Company Limited

  公开号：EP3658554A1

  公开（公告）日：2020-06-03